FibromyalgiaNCT07424534
Predictive Models on Psychosocial Profile, Fatigue and Sleep Quality
An observational study of Fibromyalgia, run by University of Castilla-La Mancha at 1 site in Spain.
Trial summary
The primary goal of this research project is to develop different prediction models in fibromyalgia disease through the application of machine learning techniques and to assess the explainability of the results. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Fibromyalgia
- How many people
- 150 participants
- Where
- 1 siteSpain
- Study dates
- 24 Feb 2026to 30 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of adult volunteers diagnosed with fibromyalgia who meet the eligibility criteria and provide written informed consent to participate in the study. Participants will be recruited from a primary care center within the Spanish public healthcare system.
Who may be able to join
- Age between 18 and 65 years.
- Fullfilled the 2010 American Collegue of Rheumathology criteria for fibromyalgia.
- Understanding of spoken and written Spanish.
Who cannot join
- Diagnosed psychiatric pathology.
- Rheumatic pathology not medically controlled.
- Neurological pathologies that make evaluations difficult.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Rafael Velasco Velasco
Seville, Seville, 41008
Rafael Velasco Velasco, Mr., +34954786735, Rafael.Velasco@uclm.es
About this study
Official title: Development of Artificial Intelligence-Based Predictive Models to Analyze the Impact of Psychosocial Profile, Fatigue, and Sleep Quality on Disease Severity in Patients With Fibromyalgia
The primary goal of this research project is to develop different prediction models in fibromyalgia disease through the application of machine learning techniques and to assess the explainability of the results. As specific objective the research project intends to evaluate the influence of psychosocial variables, fatigue, and sleep quality on the prediction of disease severity in patients with fibromyalgia using an artificial intelligence-based model.
Read the detailed description
Fibromyalgia (FM) is a condition characterized by chronic musculoskeletal pain, the pathophysiology of which remains unclear. In addition, this disorder is frequently associated with sleep disturbances, pronounced fatigue, morning stiffness, poor quality of life, cognitive alterations (primarily memory-related problems), and psychological disturbances, including depression, anxiety, and stress.
FM is significantly more prevalent in women, with an estimated female-to-male ratio of approximately 3:1. Its prevalence in the adult population is estimated at 2-3%, increasing with age and peaking between 45 and 65 years. The socioeconomic and healthcare burden of this condition is substantial, as FM is associated with high rates of medical consultations, unemployment, work disability, and the need for disability-related financial support.
FM has been linked to higher levels of negative affect, defined as a general state of distress encompassing aversive emotions such as sadness, fear, anger, and guilt. Patients with FM commonly exhibit elevated levels of anxiety, depression, pain catastrophizing, and stress, which are associated with worsening of symptoms, including cognitive impairments.
In recent years, machine learning, data mining, and artificial intelligence (AI) techniques have been successfully applied to the development of computer-aided diagnosis (CAD) systems for the identification of complex health conditions, achieving good levels of accuracy and efficiency by recognizing potentially meaningful patterns in health-related data. Accordingly, these technologies provide powerful tools for multivariable data analysis, enabling model-based predictions and offering a clear advantage in risk assessment across a wide range of diseases. In addition, these approaches not only support the development of clinical predictive models but also enhance clinicians' ability to interpret and apply their results in practice.
Explainable machine learning models allow clinical experts to make data-driven decisions and to deliver personalized treatments while maintaining a high standard of care. These models fall within the field of explainable artificial intelligence (XAI), which aims to develop interpretable models that preserve high predictive accuracy while improving the transparency, understanding, and trustworthiness of model outputs.
A previous publication by our research group demonstrated, using machine learning models, a strong association between mental health factors-particularly anxiety and depression-and fibromyalgia severity, with a greater influence than pain intensity itself. Other prevalent symptoms of fibromyalgia, such as fatigue and sleep quality disturbances, are also considered by patients to be major contributors to reduced quality of life, often perceived as more impactful than pain.
Accordingly, the present study aims to develop predictive models of fibromyalgia severity using machine learning and explainable artificial intelligence techniques, incorporating fatigue and sleep quality as novel variables in the analysis.
Understanding the individual and combined relevance of these psychosocial components in determining patients' clinical status may contribute to improved disease management and more personalized treatment strategies, ultimately enhancing the quality of care.
- Conditions
- Fibromyalgia
- Medical subject headings
- Fibromyalgia
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease severity
For this purpose, the Spanish validated version of the Fibromyalgia Impact Questionnaire (FIQ) will be used. The questionnaire comprises several components assessing physical, psychological, and social status, as well as overall well-being. It consists of 10 items scored on 0-10 scales, yielding a total score ranging from 0 to 100, with higher scores indicating greater disease impact and poorer quality of life.
Measured: Baseline
Secondary outcomes (6)
Sleep quality
Sleep quality will be assessed using the Spanish validated version of the Medical Outcomes Study Sleep Scale (MOS-SS). This instrument consists of 12 items evaluating six sleep domains: sleep disturbance (ability to initiate and maintain sleep), sleep adequacy (sufficiency of sleep to feel rested), sleep quantity (number of hours of sleep), somnolence (daytime sleepiness), snoring, and shortness of breath or headache. A sleep problems index can be derived on a 0-100 scale, with higher scores indicating greater sleep-related problems.
Measured: Baseline
Fatigue
Fatigue severity will be assessed using the Spanish adaptation of the Multidimensional Fatigue Inventory (MFI). This is a self-administered questionnaire consisting of 20 items. It comprises five subscales that analytically assess general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The total score ranges from 0 to 100, with higher scores indicating greater fatigue severity.
Measured: Baseline
Pain intensity
It will be measured with a visual analog scale (VAS) of 100 millimeters in length. The subject has to indicate the level of pain he feels, being 0 the absence of pain and 100 the maximum imaginable.
Measured: Baseline
Depression
Depressive symptoms will be assessed using the Spanish adaptation of the Beck Depression Inventory-II (BDI-II). This instrument consists of 21 items designed to measure affective and cognitive status, as well as the signs and symptoms of depression experienced over the preceding two weeks. Total scores range from 0 to 63, where higher scores indicate greater severity.
Measured: Baseline
Pain catastrophizing
The Spanish validated version of the Pain Catastrophizing Scale (PCS) will be administered. The PCS consists of 13 items assessing catastrophic cognitive-emotional processes related to pain and encompasses the three main dimensions of catastrophizing: rumination (persistent concern and inability to inhibit pain-related thoughts), magnification (exaggeration of the unpleasantness of pain and expectations of negative consequences), and helplessness (perceived inability to cope with painful situations). Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is calculated by summing the responses to all 13 items, with higher scores indicating greater levels of pain catastrophizing.
Measured: Baseline
Anxiety
Anxiety will be assessed using the Spanish validated version of the State Anxiety Scale (STAI-S) of the State-Trait Anxiety Inventory (STAI). It consists of 20 items scored on a Likert-type scale from 0 to 3. The score ranges from 0 to 60 points, with higher scores indicating worse anxiety levels.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start24 Feb 2026 (estimated)
- Primary completion30 Nov 2026 (estimated)
- Study completion30 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Castilla-La Mancha
- Sponsor type
- University, hospital or other
- Collaborators
- Tampere University, Andaluz Health Service
- Responsible party
- Sponsor
- Investigators
- Rafael Velasco Velasco, Mr., Principal investigator, University of Castilla-La Mancha
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07424534
- Sponsor's protocol ID
- FibroIA
- Status last verified
- Mar 2026
- First submitted
- 13 Feb 2026
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of Artificial Intelligence-Based Predictive Models to Analyze the Impact of Psychosocial Profile, Fatigue, and Sleep Quality on Disease Severity in Patients With Fibromyalgia
- ClinicalTrials.gov ID
- NCT07424534
- Acronym / sponsor ID
- FibroIA
- Conditions
- Fibromyalgia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University of Castilla-La ManchaUniversity, hospital or other
- Collaborators
- Tampere University, Andaluz Health Service
- Study start
- 24 Feb 2026 (estimated)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 30 Nov 2026 (estimated)
- First posted
- 20 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary goal of this research project is to develop different prediction models in fibromyalgia disease through the application of machine learning techniques and to assess the explainability of the results. As specific objective the research project intends to evaluate the influence of psychosocial variables, fatigue, and sleep quality on the prediction of disease severity in patients with fibromyalgia using an artificial intelligence-based model.
Detailed description
Fibromyalgia (FM) is a condition characterized by chronic musculoskeletal pain, the pathophysiology of which remains unclear. In addition, this disorder is frequently associated with sleep disturbances, pronounced fatigue, morning stiffness, poor quality of life, cognitive alterations (primarily memory-related problems), and psychological disturbances, including depression, anxiety, and stress.
FM is significantly more prevalent in women, with an estimated female-to-male ratio of approximately 3:1. Its prevalence in the adult population is estimated at 2-3%, increasing with age and peaking between 45 and 65 years. The socioeconomic and healthcare burden of this condition is substantial, as FM is associated with high rates of medical consultations, unemployment, work disability, and the need for disability-related financial support.
FM has been linked to higher levels of negative affect, defined as a general state of distress encompassing aversive emotions such as sadness, fear, anger, and guilt. Patients with FM commonly exhibit elevated levels of anxiety, depression, pain catastrophizing, and stress, which are associated with worsening of symptoms, including cognitive impairments.
In recent years, machine learning, data mining, and artificial intelligence (AI) techniques have been successfully applied to the development of computer-aided diagnosis (CAD) systems for the identification of complex health conditions, achieving good levels of accuracy and efficiency by recognizing potentially meaningful patterns in health-related data. Accordingly, these technologies provide powerful tools for multivariable data analysis, enabling model-based predictions and offering a clear advantage in risk assessment across a wide range of diseases. In addition, these approaches not only support the development of clinical predictive models but also enhance clinicians' ability to interpret and apply their results in practice.
Explainable machine learning models allow clinical experts to make data-driven decisions and to deliver personalized treatments while maintaining a high standard of care. These models fall within the field of explainable artificial intelligence (XAI), which aims to develop interpretable models that preserve high predictive accuracy while improving the transparency, understanding, and trustworthiness of model outputs.
A previous publication by our research group demonstrated, using machine learning models, a strong association between mental health factors-particularly anxiety and depression-and fibromyalgia severity, with a greater influence than pain intensity itself. Other prevalent symptoms of fibromyalgia, such as fatigue and sleep quality disturbances, are also considered by patients to be major contributors to reduced quality of life, often perceived as more impactful than pain.
Accordingly, the present study aims to develop predictive models of fibromyalgia severity using machine learning and explainable artificial intelligence techniques, incorporating fatigue and sleep quality as novel variables in the analysis.
Understanding the individual and combined relevance of these psychosocial components in determining patients' clinical status may contribute to improved disease management and more personalized treatment strategies, ultimately enhancing the quality of care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of adult volunteers diagnosed with fibromyalgia who meet the eligibility criteria and provide written informed consent to participate in the study. Participants will be recruited from a primary care center within the Spanish public healthcare system.
Key inclusion criteria (3 listed)
- Age between 18 and 65 years.
- Fullfilled the 2010 American Collegue of Rheumathology criteria for fibromyalgia.
- Understanding of spoken and written Spanish.
Key exclusion criteria (3 listed)
- Diagnosed psychiatric pathology.
- Rheumatic pathology not medically controlled.
- Neurological pathologies that make evaluations difficult.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Disease severity
Time frame: Baseline
For this purpose, the Spanish validated version of the Fibromyalgia Impact Questionnaire (FIQ) will be used. The questionnaire comprises several components assessing physical, psychological, and social status, as well as overall well-being. It consists of 10 items scored on 0-10 scales, yielding a total score ranging from 0 to 100, with higher scores indicating greater disease impact and poorer quality of life.
6 secondary outcomes
Sleep quality
Time frame: Baseline
Fatigue
Time frame: Baseline
Pain intensity
Time frame: Baseline
Depression
Time frame: Baseline
Pain catastrophizing
Time frame: Baseline
Anxiety
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
Related trials for Fibromyalgia
Active, not recruiting
Objective Measurement of Pain Regulation in Individuals Who Have Received Internet-delivered Exposure-based Cognitive Behavior Therapy
Fibromyalgia
Enrolling by invitationPhase 3
Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia
Fibromyalgia
Recruiting
Exercise Interventions and Dietary Advice in Fibromyalgia and IBS
Fibromyalgia, Irritable Bowel Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Recruiting
Auricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia
Fibromyalgia Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rafael Velasco Velasco, Mr. principal investigator
University of Castilla-La Mancha
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fibromyalgia, run by University of Castilla-La Mancha at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rafael Velasco Velasco, Mr. (+34954786735, Rafael.Velasco@uclm.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease severity (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.